To OTC Journal Members:
 

Comments in the BLOG

Nothing new to report in the BLOG for last week. I like to use the BLOG for volatile markets, and we haven't seen much volatility lately. There continues to be some contributions on ZAP- check out the comments. There are some participants that don't think too highly of the company, and negative postings are there so you can get both sides of the story. By definition, this is a bias publication, but I believe you should have both the positives and negatives on any company.

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. The most current journal entries appear in the middle of your screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels or in volatile markets. Your questions and postings do not automatically appear, so don't bother posting the same question multiple times. I personally go through to moderate and respond to every question.
 

Xenomics (OTC BB: XNOM) Getting Favorable Recognition

XNOM has been perking up of late, and I'm getting a lot of email traffic wondering why. XNOM is starting to get buzz in the medical diagnostics community, and investors are catching on to the depth and importance of their technology.

In recent news, XNOM disclosed it would be starting clinical trials with two highly respected east coast hospitals in the near future. Their transrenal DNA test for Downs Syndrome is truly revolutionary and once approved, should replace Amniocentisis as the method for testing high risk pregnancies with a simple urine sample. 

Their test will be designed to replace the current triple screen test given to all high risk pregnancies. There are about 2 million triple screen tests performed in the US every year, so the market has significant profit potential.

The current triple screen test only provides a risk assessment, not a definitive result. In the case of a high risk result, further tests must be performed.

The medical community is taking note of XNOM because they have discovered two “Methylation” Markers that are positive in volunteer Down syndrome patients and negative in normal controls.  North Shore and EVMS hospitals will be providing the clinical samples to validate these markers and determine the sensitivity and specificity of the method under development.  This is a huge turning point for XNOM, and the stock is getting traction as word of their discovery is spreading.

Many biotech companies are focusing a great deal of energy in the cell-free circulating plasma DNA field looking for “methylation” markers. XNOM believes it is the first two discover markers for Downs Syndrome as no other company has made any public claims.

XNOM clinical trials will be under way soon, and sensitivities and specificities will be determined from the data. However, most DNA-based tests have sensitivities in the 90%+ range and the XNOM tests should not be any different.  The current triple and quad screen tests have sensitivity at 65% and 75% respectively.

On March 17, 2005, I published our first feature on XNOM. The stock closed at $2.50 that day. Six weeks later the stock is trading at $3.25 for a 29% return. This is a nice surprise in a very lackluster market.

As you can see from the chart, the stock has begun a nice climb phase, and I don't know where it will peak. The stock does not have a long standing trading history, so it is impossible to make any valid technical comments.

I continue to believe this is an exciting idea for long term investors. This company will become the leader in the use of transrenal dna technologies.

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketBtye LLC has been paid a fee of $30,000 by Xenomics for coverage of the company. In addition, as part of the compensation package,  MarketByte LLC has been awarded 100,000 warrants with an exercise price of $2.95, convertible into restricted shares, by Trilogy Capital for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. 

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services. 

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner.  No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors may or may not own shares in the companies that it so refers to MarketByte.  MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.